Skip to content

Specific Biomarkers of Immune-mediated Hepatitis Secondary to Immune Checkpoint Inhibitors

Specific Biomarkers of Immune-mediated Hepatitis Secondary to Immune Checkpoint

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06470997
Acronym
Pro-CHILI
Enrollment
60
Registered
2024-06-24
Start date
2024-07-17
Completion date
2027-01-31
Last updated
2025-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immune-mediated Hepatitis

Keywords

proteomic analysis, blood biomarker, immune-mediated hepatitis secondary to immune checkpoint inhibitors, idiopathic autoimmune hepatitis

Brief summary

Identify specific blood biomarkers for hepatitis induced by immune checkpoint inhibitors in comparison to idiopathic autoimmune hepatitis.

Detailed description

Immune checkpoint inhibitors (ICI) have become a pillar of the oncological therapeutic arsenal. Their mechanism of action is based on the restoration of the innate anti-tumor function of T lymphocytes. This mode of action is also the cause of systemic immune-mediated adverse effects. The most common disorders are endocrine, cutaneous and gastrointestinal. The frequency of hepatic toxicities is estimated between 0.7 and 25% depending on the studies, the cancer treated and the ICI combinations used. Currently the description of these hepatitis is brief in the literature and the mechanism of toxicity is not known. Work has already compared histological damage between immune checkpoint inhibitors (CHILI) and autoimmune hepatitis; The investigators find in CHILI a higher ratio of CD8 + /CD4 + lymphocytes. Apart from these clinical, biological or histological descriptions, knowledge is limited. In particular, there are no known predictive factors or prognoses. The investigators hypothesize that there are mechanistic differences between checkpoint inhibitors induced liver injury and idiopathic autoimmune liver disease. Proteomic analysis is a powerful tool for functional analysis.

Interventions

BIOLOGICALBlood sample collection

6 collections of 5mL blood samples as part of usual care (pre-inclusion visit at Day-7, inclusion visit at Day 0, visit1 at Day 14, visit2 at Day 28, visit3 at Day 90, visit4 at 6 months) and 5 blood sample collections of 5 mL for proteomic analysis in the context of research (inclusion visit at Day 0, visit1 at Day 14, visit2 at Day 28, visit3 at Day 90, visit4 at 6 months)

PROCEDURELiver biopsy

1 liver biopsy performed as part of routine care and 1 additional sample for research: transparietal needle biopsy under ultrasound identification under local anesthesia by a radiologist, 1 to 2 cm per core taken, 2 cores are taken.

Sponsors

University Hospital, Montpellier
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

for patients in the CHILI group: * Patient \> 18 years old * Patient treated with immune checkpoint inhibitors (ICI) alone or in combination * Patient suffering from Hepatitis secondary to immune checkpoint inhibitors (ICI) grade 3 or 4 Common Terminology Criteria For Adverse Events (CTCAE)\* * Treatment with corticosteroids or Ursodeoxycholic acid (UDCA) not started, or started less than 30 days ago * Grade 3 or 4 hepatitis: increase in transaminases and/or alkaline phosphatases ≥ 5 x Upper Limit of Normal (ULN) or total bilirubin ≥ 3 Inclusion criteria for patients in the control group: * Patient \> 18 years old * Patient suffering from Primary Biliary Cholangitis (PBC)\* or Autoimmune Hepatitis (AIH)\*\* or Primary Sclerosing Cholangitis (PSC) \*\*\* Primary Biliary Cholangitis (PBC)\* diagnosis : Association of at least 2 of the following 3 criteria : * Cholestasis (PAL \> 1.5N, Gamma GT \> 3N) chronic (\> 6 months) without ultrasound abnormality of the bile ducts. * M2 type anti-mitochondria Ab \> 1/40th * Characteristic histological lesions (non-suppurative destructive cholangitis) or compatible (portal inflammation, granulomas, ductular proliferation, ductopenia, cholestasis). \*\* AIH diagnosis : ALT \> 5 N / Ig G \> 1.5 - 2 N or anti-smooth muscle ≥ 1/80 / Interface hepatitis of marked intensity The Hepactic Activity Index (HAI) score makes it possible to confirm the diagnosis when all the diagnostic criteria are not met. \*\*\* PSC diagnosis: presence of chronic cholestasis (alkaline phosphatase \> 1.5 N or GGT \> 3 N) and typical abnormalities of the bile ducts on cholangio-MRI (Magnetic Resonance Imaging), and in the absence of cause of secondary sclerosing cholangitis * Treatment with corticosteroids or Ursodeoxycholic acid (UDCA) not initiated, or started less than 30 days ago Non-inclusion criteria: * Impossibility of following the patient during the study period * Liver biopsy not possible * Other hepatitis diagnoses * Failure to obtain consent * Unemancipated minors, people unable to express their consent * Non-affiliation to a social security or equivalent scheme, * Persons placed under judicial protection, * Person participating in another research including a period of exclusion still in progress. * Pregnant or breastfeeding women * De novo or old diagnosis (at the time of a flare-up)

Design outcomes

Primary

MeasureTime frameDescription
Determination of the area under the ROC (Receiver Operation characteristic) curve for hepatitis.BaselineSensitivity/specialty curve of blood biomarkers identification and expression level by proteomic analysis, specific to immunotherapy-induced hepatitis (CHILI group), versus idiopathic autoimmune hepatitis (control group).

Secondary

MeasureTime frameDescription
Determination of the area under the ROC (Receiver Operation characteristic) curve for treatment responseBaseline, day 14, day 28, month 3, month 6Sensitivity/specialty curve of blood biomarkers identification and expression level by proteomic analysis, specific to response to treatments corticosteroids, UDCA (Ursodeoxycholic acid) established as part of the care).
Responses to treatmentsDay 28Response to corticosteroid and UDCA (Ursodeoxycholic acid) treatments being defined as a reduction in liver tests of 50%

Countries

France

Contacts

Primary ContactLucy MEUNIER, MD
lucy-meunier@chu-montpellier.fr0467330224
Backup ContactLina HOUNTONDJI, MD
l-hountondji@chu-montpellier.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026